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Although metastatic breast cancer (MBC) may be responsive
to further treatment, it is incurable, and so improving the
quality of life (QoL), not merely the length of life, is an
important parameter of benefit. Patients need appropriate
formal psychosocial assessment to enable identification of
those who may require different forms of support in order to
minimize the social and emotional impact of the diagnosis
and effects of treatment. Between 31% and 57% of women
with MBC will have a mood disorder that merits intervention
[1,2], but oncologists are not very skilled at recognizing
psychological distress and then referring patients for
specialist help [3,4]. This means that patients’ psychological
needs may go unrecognized, underestimated and under-
treated. Some countries may well have resource constraints
that limit access to specialist supportive care provided by
breast care nurses, trained counsellors, clinical psycho-
logists, liaison psychiatrists and others, but a clear evidence
base exists from at least five meta-analyses that demonstrates
the efficacy of psychosocial interventions in adult cancer
patients [5-9]. In MBC specifically, the benefits of inter-
ventions such as group support [10,11] and cognitive
behaviour therapy [12] have been demonstrated. The UK and
Australia have both produced national guidelines and
guidance about the provision of supportive services [13,14].
Patient well being, length of life and QoL must always be the
main factors that influence decisions about treatment;
however, the accuracy and reliability of clinicians’ assess-
ments of well being and QoL in busy clinics is questionable. I
have referred above to the difficulty oncologists have in
detecting psychological morbidity; some might argue that
they are trained in cancer medicine not psychiatry, but how
reliable is their detection of other cancer treatment related
problems that might influence a patient’s well being? Studies
show that monitoring of other troubling treatment-related side
effects and symptoms is also rather poor when patient
recorded outcomes are compared with those recorded by
physicians. Observation of oncologists working in busy
clinics shows that the manner in which adverse events and
side effects are recorded is not especially reliable. For
example, even within the relatively tightly controlled setting of
a clinical trial, the sensitivity and specificity of the detection of
common chemotherapy side effects are unacceptably low
[15]. Several other studies have examined the lack of
congruence between patient and physician recording of side
effects that have an impact on QoL; many are either under-
estimated or unrecognized altogether by clinicians [16-18].
This is serious because accurate recognition of bothersome
side effects could influence the initiation, continuation,
change, or termination of therapy, and may prompt timely
instigation of other supportive and ameliorative interventions.
Information from patient self-report questionnaires may
provide a different viewpoint about tolerability and toxicity that
is not always recognized as important by health care
professionals, and accumulation and discussion of such
information enables patients to make more informed choices
regarding their treatment options. Some of the side-effects of
treatment, especially vasomotor complaints, affect adherence
to treatment even in women with advanced disease [19].
Despite the evidence supporting formal data collection,
patient self-report assessments still fail to influence
management decisions as much as traditional outcomes,
such as tumour markers or other objective measures. This is
curious given accumulating data from studies in metastatic
melanoma, colorectal, lung and breast cancer that
demonstrate the predictive and prognostic value of baseline
QoL measurement [20]. This predictive information is
independent of that derived from other orthodox measures
[21]. Studies in patients with advanced breast cancer
indicated that regular assessment revealed a decline in QoL
scores when disease ceased to respond to chemotherapy,
and again this occurred before any indications from other
objective measures [22].
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Collection of data from formal QoL instruments broadens the
parameters of benefit beyond response and survival, and
allows a more accurate determination of the supportive and
ameliorative interventions that patients with MBC require. The
challenge of how to convince clinicians of its value remains.
Many worry about the practical difficulties of administering,
scoring and interpreting QoL questionnaires, although some
researchers have achieved this successfully in their own
routine oncology practice [23]. Recently published
recommendations from the European School of Oncology
have stated the importance of thorough QoL assessment in
MBC [24].
It is interesting that the practical and financial burdens
associated with measuring tumour markers, despite the
questionable utility of these in MBC, do not appear to have
been subjected to the scepticism and scrutiny that is
reserved for formal measurement of QoL variables.
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